Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment

European Urology

Volumn 55, Issue 6, 2009, Pages 1440-1449

  Roosen, Alexander ^a,e   Datta, Soumendra N ^a   Chowdhury, Rasheda A ^b   Patel, Pravina M ^b   Kalsi, Vinay ^a   Elneil, Sohier ^a   Dasgupta, Prokar ^a,c   Kessler, Thomas M ^a   Khan, Shahid ^a   Panicker, Jalesh ^a   Fry, Christopher H ^d   Brandner, Sebastian ^a   Fowler, Clare J ^a   Apostolidis, Apostolos ^a,f  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Botulinum toxin A; Connexin 43; Detrusor overactivity; Gap junction; Myofibroblast; Suburothelium

Indexed keywords

BIOLOGICAL MARKER; BOTULINUM TOXIN A; CONNEXIN 43; STEM CELL FACTOR; VIMENTIN;

ADULT; ARTICLE; BLADDER BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPE; DRUG EFFECT; FEMALE; GAP JUNCTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MYOFIBROBLAST; OPEN STUDY; OVERACTIVE BLADDER; PELVIS SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UROTHELIUM;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; BOTULINUM TOXINS, TYPE A; CONNEXIN 43; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEUROMUSCULAR AGENTS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS; UROTHELIUM;

EID: 65049086947     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.11.009     Document Type: Article

References (33)

1. Wiseman O.J., Fowler C.J., and Landon D.N. The role of the human bladder lamina propria myofibroblast. BJU Int 91 (2003) 89-93
2. Fry C.H., Sui G.P., Kanai A.J., and Wu C. The function of suburothelial myofibroblasts in the bladder. Neurourol Urodyn 26 (2007) 914-919
3. Ikeda Y., Fry C., Hayashi F., Stolz D., Griffiths D., and Kanai A. Role of gap junctions in spontaneous activity of the rat bladder. Am J Physiol Renal Physiol 293 (2007) F1018-F1025
4. Sui G.P., Wu C., Roosen A., Ikeda Y., Kanai A.J., and Fry C.H. Modulation of bladder myofibroblast activity: implications for bladder function. Am J Physiol Renal Physiol 295 (2008) F688-F697
5. Neuhaus J., Pfeiffer F., Wolburg H., Horn L.C., and Dorschner W. Alterations in connexin expression in the bladder of patients with urge symptoms. BJU Int 96 (2005) 670-676
6. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 (2000) 692-697
7. Ehren I., Volz D., Farrelly E., et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41 (2007) 335-340
8. Kalsi V., Apostolidis A., Gonzales G., Elneil S., Dasgupta P., and Fowler C.J. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 54 (2008) 181-187
9. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., and Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535
10. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
11. Apostolidis A., Popat R., Yiangou Y., et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977-982 discussion 982-3
12. Morenilla-Palao C., Planells-Cases R., Garcia-Sanz N., and Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279 (2004) 25665-25672
13. Anderson S., DiCesare L., Tan I., Leung T., and SundarRaj N. Rho-mediated assembly of stress fibers is differentially regulated in corneal fibroblasts and myofibroblasts. Exp Cell Res 298 (2004) 574-583
14. Ishida H., Zhang X., Erickson K., and Ray P. Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther 310 (2004) 881-889
15. Ronnov-Jessen L., and Petersen O.W. ADP-ribosylation of actins in fibroblasts and myofibroblasts by botulinum C2 toxin: influence on microfilament morphology and migratory behavior. Electrophoresis 17 (1996) 1776-1780
16. Harper M., Popat R.B., Dasgupta R., Fowler C.J., and Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
17. Dasgupta P., Chandiramani V.A., Beckett A., Fowler C.J., Crowe R., and Shah P.J. Flexible cystoscopic biopsies for evaluation of nerve densities in the suburothelium of the human urinary bladder. Br J Urol 80 (1997) 490-492
18. Schulte-Baukloh H., and Knispel H.H. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 95 (2005) 454
19. Drake M.J., Fry C.H., and Eyden B. Structural characterization of myofibroblasts in the bladder. BJU Int 97 (2006) 29-32
20. Sui G.P., Rothery S., Dupont E., Fry C.H., and Severs N.J. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 90 (2002) 118-129
21. Davidson R.A., and McCloskey K.D. Morphology and localization of interstitial cells in the guinea pig bladder: structural relationships with smooth muscle and neurons. J Urol 173 (2005) 1385-1390
22. van der Aa F., Roskams T., Blyweert W., Ost D., Bogaert G., and De Ridder D. Identification of kit positive cells in the human urinary tract. J Urol 171 (2004) 2492-2496
23. Kubota Y., Hashitani H., Shirasawa N., et al. Altered distribution of interstitial cells in the guinea pig bladder following bladder outlet obstruction. Neurourol Urodyn 27 (2008) 330-340
24. Biers S.M., Reynard J.M., Doore T., and Brading A.F. The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor. BJU Int 97 (2006) 612-616
25. Christ G.J., Day N.S., Day M., et al. Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol 284 (2003) R1241-R1248
26. Haefliger J.A., Tissieres P., Tawadros T., et al. Connexins 43 and 26 are differentially increased after rat bladder outlet obstruction. Exp Cell Res 274 (2002) 216-225
27. Li L., Jiang C., Hao P., Li W., Song C., and Song B. Changes of gap junctional cell-cell communication in overactive detrusor in rats. Am J Physiol Cell Physiol 293 (2007) C1627-C1635
28. Haferkamp A., Mundhenk J., Bastian P.J., et al. Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol 46 (2004) 799-805
29. Wu C., Sui G.P., and Fry C.H. Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol 559 (2004) 231-243
30. Apostolidis A., Jacques T.S., Freeman A., et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53 (2008) 1245-1253
31. Brady C.M., Apostolidis A., Yiangou Y., et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 46 (2004) 247-253
32. Apostolidis A., Brady C.M., Yiangou Y., Davis J., Fowler C.J., and Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 65 (2005) 400-405
33. Mukerji G., Yiangou Y., Grogono J., et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176 (2006) 367-373